Clinical Trials Browser

INDUSTRY × Solid Tumors × CB-839 × Clear all

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumors